Cwm LLC Boosts Stake in Jazz Pharmaceuticals PLC $JAZZ

Cwm LLC increased its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 197.1% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 3,740 shares of the specialty pharmaceutical company's stock after purchasing an additional 2,481 shares during the period. Cwm LLC's holdings in Jazz Pharmaceuticals were worth $397,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Philip James Wealth Mangement LLC lifted its holdings in shares of Jazz Pharmaceuticals by 42.0% in the 2nd quarter. Philip James Wealth Mangement LLC now owns 15,797 shares of the specialty pharmaceutical company's stock valued at $1,676,000 after purchasing an additional 4,675 shares during the last quarter. State of Alaska Department of Revenue raised its stake in Jazz Pharmaceuticals by 75.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 57,933 shares of the specialty pharmaceutical company's stock valued at $6,147,000 after acquiring an additional 24,850 shares during the last quarter. Inspire Investing LLC purchased a new stake in Jazz Pharmaceuticals during the 1st quarter valued at approximately $689,000. Baird Financial Group Inc. purchased a new stake in Jazz Pharmaceuticals during the 1st quarter valued at approximately $539,000. Finally, Voya Investment Management LLC raised its stake in Jazz Pharmaceuticals by 67.1% during the 1st quarter. Voya Investment Management LLC now owns 56,349 shares of the specialty pharmaceutical company's stock valued at $6,996,000 after acquiring an additional 22,628 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 3,500 shares of the stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $140.00, for a total transaction of $490,000.00. Following the sale, the director owned 408,826 shares in the company, valued at approximately $57,235,640. This represents a 0.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders sold 11,500 shares of company stock worth $1,525,280. 4.30% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Stock Performance

JAZZ opened at $138.53 on Friday. The stock has a market cap of $8.40 billion, a P/E ratio of -20.58, a P/E/G ratio of 8.23 and a beta of 0.28. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The stock's 50 day simple moving average is $130.44 and its 200 day simple moving average is $117.00. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). The firm had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business's revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, equities analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on JAZZ. The Goldman Sachs Group upped their price objective on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a "buy" rating in a research note on Friday, August 29th. Morgan Stanley set a $183.00 price objective on Jazz Pharmaceuticals in a research note on Friday. Royal Bank Of Canada upped their price objective on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an "outperform" rating in a research note on Thursday, August 28th. Weiss Ratings reissued a "sell (d)" rating on shares of Jazz Pharmaceuticals in a research note on Saturday. Finally, Zacks Research raised Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Friday, August 15th. Fourteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Jazz Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $180.00.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.